Abcellera Biologics is trading 4.2% down at $6.51 as investors continue to take profits following a rally of more than 40% driven by upbeat Q1 2026 results and pipeline optimism.
- The stock's decline follows a period of significant outperformance fueled by positive sentiment surrounding the company's clinical pipeline.
- Broader pressure is weighing on the biotech sector, with the XBI ETF falling approximately 3% amid a general sell-off in high-beta names.
- Market participants appear to be locking in gains as the industry faces broader macro-driven profit-taking.